Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.